Introduction {#sec1-2054270414540139}
============

Scars are the end outcome of the natural healing and reparative process as a result of dermal fibrotic scar formation postinflammation. They have been categorised according to clinical and histological appearance into various categories: keloid, hypertrophic, stretched and atrophic scars. Atrophic scars are broadly described as exhibiting generalised cutaneous atrophy resulting in loss of cutaneous cells in the epidermis although appear clinically as a loss of normal dermis. Clinically, atrophic scars classically appear as depressions of the skin and commonly occur post acne amongst other causes listed in [Table 1](#table1-2054270414540139){ref-type="table"}. Table 1.Main causes and risk factors for developing atrophic scars.Cause/risk factorInflammatoryAcneCystDiscoid lupus erythematosusInfectivePostvaricellaTraumaInjuryBurnIatrogenic -- surgeryPatient factorsTendency toward atrophic scarringPrevious atrophic scarsEhlers--Danlos syndromePrimary anetoderma

There are various atrophic scar treatment modalities in this clinical area of interest. This article aims to describe and evaluate the evidence in published literature including randomised controlled trials (RCTs) for atrophic scarring. The method of evaluation of studies will be via the Clinical Evidence GRADE score, which assigns a score to categorise all interventions according to their likely effectiveness based on type of study, quality, dose response, consistency of results and significance of results.

Methods {#sec2-2054270414540139}
=======

We conducted a Medline, EMBASE, Cochrane and CINHL search to retrieve any studies including RCTs evaluating treatment modalities for atrophic scarring. Key words used in each search engine included (with wildcard truncation used as\*) atrophic, scar\*, therapeutics (mapped to thesaurus to include treatment, intervention), drug treatment, conservative treatment, surgery, laser, treatment outcome and treatment response. We excluded journal letters and interventions on paediatric patients. We included all English publications published in any year analysing the effectiveness of treatment modalities for atrophic scarring. A total of 45 studies were identified which included RCTs, observational studies, retrospective analyses and case reports. No review articles were identified.

All abstracts of studies found were assessed by two independent clinicians against criteria for inclusion to ensure applicability of study within the systematic review. Randomised control trials were included regardless of the length of follow-up period or patient drop-out rate and those that were at least single blinded. A final number of 41 studies were identified.

Having retrieved the full articles of all studies identified, each study was evaluated with the GRADE Clinical Evidence score as per parameters shown in [Table 2](#table2-2054270414540139){ref-type="table"}.^[@bibr1-2054270414540139]^ The scoring system aimed to assess the type of study, quality, consistency, directness and effect size allowing the overall score to rate the study as high, moderate, low or very low in terms of intervention effectiveness for atrophic scarring. Table 2.Clinical evidence GRADE score components (adapted from Clinical Evidence^[@bibr1-2054270414540139]^).ParameterAreas examined within parameter for each studyScoreScore explainedType of evidenceRCTs/SR of RCTs+4Observational evidence (e.g. cohort, case--control)+2QualityBlinding and allocation process0No problemsFollow-up1Problem with 1 elementWithdrawal of participants2Problem with 2 elementsSparsity of data3Problem with 3 elementsConsistencyDegree of consistency of effect between or within studies+1Evidence of dose response across or within studies (or inconsistency across studies is explained by a dose response); also 1 point added if adjustment for confounders would have increased the effect size0All/most studies show similar results1Lack of agreement between studies (e.g. statistical heterogeneity between RCTs, conflicting results)DirectnessThe generalisability of population and outcomes from each study to population of interest0Population and outcomes broadly generalisable1Problem with 1 element2Problem with 2 or more elementsEffect sizeThe reported OR/RR/HR for comparison0Not all effect sizes \>2 or \<0.5 and significant; or if OR/RR/HR not significant+1Effect size \>2 or \<0.5 for all studies/meta-analyses included in comparison and significant+2Effect size \>5 or \<0.2 for all studies/meta-analyses included in comparison and significant[^1][^2]

Results {#sec3-2054270414540139}
=======

Forty-one studies reporting treatments for atrophic scars were identified including randomised control trials (8), retrospective cohort study analysis (8), prospective cohort analysis (21) and case studies (4) as demonstrated in [Figure 4](#fig4-2054270414540139){ref-type="fig"}.

The available treatment modalities for atrophic scarring available in literature are ablative fractional laser therapy (6), non-ablative laser therapy (16), dermabrasion (2), chemical peel therapy (5), surgical techniques such as subcision, autologous fat transfer and injectables (5) and combination therapies (7) highlighted in [Table 3](#table3-2054270414540139){ref-type="table"}. Table 3.Atrophic scar treatment modality and GRADE scoring.AuthorsTreatment modalityScoreStudy designOutcomeCO~2~ ablative laserHedelund *et al.* ^[@bibr2-2054270414540139]^CO~2~ laser re-surfacing vs. placebo+5RCT (single blinded): 12 patients treated with randomised split face treatment three times in 4/5-week intervals. Followed up till six months.Objective, statistically assessed increase in scar smoothness.Walia and Alster^[@bibr3-2054270414540139]^CO~2~ laser re-surfacing+3Observational: 60 patients with acne atrophic scars treated with laser re-surfacing and assessed between 1 and 18 months with biopsies.Subject investigator improvement scores and positive histological evidence of new collagen deposition.Weiss *et al.* ^[@bibr4-2054270414540139]^CO~2~ ablative fractional therapy−3Observational: 19 non-acne atrophic scars treated with three treatments of ablative fractional therapy at 1--4-month intervals and followed up for six months.Subjective patient and investigator improvement scores and non-significant objective topographical analysis improvement.Cho *et al.* ^[@bibr5-2054270414540139]^CO~2~ ablative fractional therapy−3Observational: 20 acne atrophic scars treated with ablative fractional therapy and followed up for three months.Subjective patient and investigator improvement scoresKim^[@bibr6-2054270414540139]^CO~2~ laser−3Observational: 35 acne atrophic scar patients treated with five sessions at 2--3-week intervals of pinpoint CO~2~ laser, nil long-term follow-up.Subjective patient and investigator improvement scores.Manuskiatti *et al.* ^[@bibr7-2054270414540139]^CO~2~ ablative therapy−1Observational: 13 acne atrophic scar patients treated with three seven-weekly laser sessions and followed up till six months.Objective and subjective patient and investigator improvement scoresNon-ablative laserTanzi and Alster^[@bibr8-2054270414540139]^1450 nm diode laser vs. 1320 nm Nd:YAG laser+5RCT (single blinded): 20 atrophic scar patients received split face laser treatments at three-week intervals and followed up for 12 months.Significant increased histological deposition of collagen for both and improved objective photographic scar quality for both.Min *et al.* ^[@bibr9-2054270414540139]^Laser: long-pulse vs. combined 585/1064 nm+4RCT (single blinded): 19 patients with acne atrophic scars received split face long laser and combined at two-week intervals and followed up for 14 weeks.Objective investigator and patient improvement scores for both treatments but nil significant difference between treatments. Significantly increased histological collagen deposition for both but nil significant difference between treatments.Wanitphakdeedecha *et al.* ^[@bibr10-2054270414540139]^Er YAG laser: short pulse vs. extra long pulse+3RCT (single blinded): 22 patients with atrophic acne scars randomised to treatment with SP or ELP for two sessions monthly. Followed up till four months.Objective investigator improvement scores.Hedelund *et al.* ^[@bibr11-2054270414540139]^Fractional non-ablative laser, 1540 nm laser vs. control+2RCT (single blinded): 10 patients randomised to 1540 nm laser vs. no therapy. Laser therapy given four weekly three times. Followed up till 12 weeks after last laser session.Objective investigator and patient improvement scoresChan *et al.* ^[@bibr12-2054270414540139]^Non-ablative laser+2Retrospective analysis: 47 acne atrophic patients who received non-ablative laser treatment between December 2005 and February 2009.Objective improvement in scar texture, pigmentation and extentChua *et al.* ^[@bibr13-2054270414540139]^Non-ablative 1450 nm diode laser+1Retrospective analysis: 57 acne atrophic patients who received laser treatment from May 2002 to December 2003.Objective patient and investigator improvement scores.Sadick and Schecter^[@bibr14-2054270414540139]^Laser: Nd YAG 1320 nm−1Observational: eight patients with atrophic acne scars given × 3 treatments of laser. Followed up for six months to one year.Objective patient and investigator improvement scores.Chan *et al.* ^[@bibr15-2054270414540139]^Laser re-surfacing−1Observational: 27 acne atrophic patients treated for six months with laser and followed up till 18 months.Subjective increase in investigator and patient scores, objective histological increase in collagen and objective improvement in scar viscoelasticity.Rogachefsky *et al.* ^[@bibr16-2054270414540139]^Laser re-surfacing−1Observational: 12 patients with acne atrophic scars treated with × 3 laser treatment at one-monthly intervals and followed up till six months.Objective patient and investigator improvement scores.Badawi *et al.* ^[@bibr17-2054270414540139]^Non-ablative 1064 laser−1Retrospective analysis: 22 acne atrophic patients who received six months of laser treatment between February and July 08.Objective improvement in scar improvement, texture and postinflammatory hyperpigmentation.Jih *et al.* ^[@bibr18-2054270414540139]^1450 nm diode laser−3Case study analysisSubjective investigator and patient improvement scoresTanzi and Alster^[@bibr19-2054270414540139]^2940 nm Er YAG laser−3Observational: 25 patients treated with laser and followed up till 12 months.Subjective investigator improvement scoresPark *et al.* ^[@bibr20-2054270414540139]^Fractional photothermolysis−3Observational: 59 patients with atrophic scars treated with photothermolysis at 3--4-week sessions for three weeks.Subjective investigator and patient improvement scores and increased collagen on biopsyCho *et al.* ^[@bibr21-2054270414540139]^Fractional photothermolysis−3Observational: 12 acne atrophic scar patients treated with × 3 1550 nm Erb laser at monthly intervals and followed up till four months.Subjective investigator and photographic improvement scoresDeng *et al.* ^[@bibr22-2054270414540139]^Fractional photothermolysis laser−3Observational: 26 acne atrophic scar patients treated with laser, follow-up time not specified.Subjective patient and investigator improvement scoresKoo *et al.* ^[@bibr23-2054270414540139]^Laser punch out−3Observational: 71 patients with acne atrophic scars treated with laser punch out and followed up till 12 months.Subjective patient and investigator improvement scoresAutologous fat transferRoh *et al.* ^[@bibr24-2054270414540139]^Autologous fat transfer−3Retrospective study: 20 scleroderma atrophic scar patients treated with three-weekly intervals of fat transfer identified from lower abdomen or buttocks. Followed up till 12 months.Subjective investigator improvement scoresLapiere *et al.* ^[@bibr25-2054270414540139]^Autologous fat transfer−3Two case studies of atrophic scar patients treated with fat transfer.Subjective investigator and patient improvement scoresDermabrasionBagatin *et al.* ^[@bibr26-2054270414540139]^Dermabrasion−3Observational: seven patients on oral isotretinoin for acne atrophic scarring treated with manual dermabrasion and followed up till 180 days.Subjective photographic evidence improvementMajid^[@bibr27-2054270414540139]^Microneedling−3Observational: 36 patients with facial atrophic scars of various aetiology treated with maximum of four months derma roller treatment and followed up till two months.Subjective patient and investigator improvement scores.Chemical peelsErbagci and Akcah^[@bibr28-2054270414540139]^Glycolic acid peel: daily application vs. biweekly+3RCT (Single blinded): 48 patients randomised to (a) biweekly peels (b) daily peels (c) control and followed up till 24 weeksObjective patient and investigator improvement scores with biweekly peels vs. daily peels.Barikbin *et al.* ^[@bibr29-2054270414540139]^TCA peel−1Observational: 100 varicella atrophic scar patients received 70% TCA and followed up in 12 weeks.Subjective improvement in investigator and patient scores.Lee *et al.* ^[@bibr30-2054270414540139]^TCA via CROSS method−2Retrospective analysis of 58 acne atrophic patients treated with 65% or 100% TCA via CROSS method.Subjective patients and investigator improvement scores, better scores with higher concentration.Fabbrocini *et al.* ^[@bibr31-2054270414540139]^CROSS technique: 50% TCA−3Observational: five patients with acne atrophic scars treated with three TCA treatments at four-weekly intervals. Followed up at end of last treatment.Subjective patient and investigator improvement scores and increased collagen deposition histologicallyKhunger *et al.* ^[@bibr32-2054270414540139]^CROSS technique: 100% TCA−3Observational: 30 acne atrophic scar patients treated with four two-weekly sessions of 100% TCA and followed up at three months.Subjective patient and investigator improvement scoresInjectablesSadove^[@bibr33-2054270414540139]^Injectable poly-L-lactic acid−3Two case study analyses of PLLA treated atrophic acne scars.Subjective investigator improvement scoresRichards and Rashid^[@bibr34-2054270414540139]^Hyaluronic acid filler−3Case report of atrophic treated with hyaluronic acid filler.Subjective patient improvementSubcisionHarandi *et al.* ^[@bibr35-2054270414540139]^Subcision -- suction combination+2Observational: 58 acne atrophic patients treated with subcision and then suction therapy. Followed up till six months.Objective investigator and patient improvement scoresOtherLeheta *et al.* ^[@bibr36-2054270414540139]^Percutaneous collagen induction vs. 100% TCA+3Randomised (single blinded) study: 30 patients randomised to four sessions of TCA/PCI at four-weekly intervals.Objective patient and investigator improvement scores.Kim and Cho^[@bibr37-2054270414540139]^Ablative fractional laser vs. combined ablative and non-ablative laser0RCT (single blinded): 20 patients randomly received split face ablative fractional therapy on one half and ablative fractional therapy plus non-ablative laser on the other. Followed up at four weekly intervals.Objective patient and investigator improvement scores, better results with combination therapy.Sage *et al.* ^[@bibr38-2054270414540139]^Subcuticular incision vs. porcine collagen0RCT (single blinded): nine patients underwent random split face treatment of incision on one half and collagen on other. Followed up till six months.Objective patient improvement scores of incision vs. collagen, nil significant investigator improvement between both.Epstein and Spencer^[@bibr39-2054270414540139]^Subcision and artefill filler−3Observational: 14 patients treated with subcision and then artefill. Followed up till eight months.Subjective patient and investigator improvement scores.Kang *et al.* ^[@bibr40-2054270414540139]^Dot peeling and subcision and fractional laser−3Observational: 10 patients with atrophic acne scars each received 3--4 treatments of laser monthly. Then two weeks after, received dot and subcision treatment together. Total treatment for one year and followed up at three months after all combined.Subjective investigator improvement scoresCarniol *et al.* ^[@bibr41-2054270414540139]^1450 nm laser and 30% TCA combined therapy−3Observational: nine atrophic scar patients received four-monthly laser treatment followed by bimonthly 30% TCA peels.Subjective increased investigator and patient improvement scores.Schmidt *et al.* ^[@bibr42-2054270414540139]^Tretinoin iontophoresis−3Observational: 32 patients treated with tretinoin iontophoresis and followed up.Subjective investigator and patient improvement scores. Nil significant histological collagen deposition.[^3]

Of these studies, three were allocated a high GRADE score (7%), four studies scored as moderate (10%), three scored as low (7%) and the majority of 31 studies scored very low (75%), demonstrated in [Figure 5](#fig5-2054270414540139){ref-type="fig"}.

Of the eight RCTs evaluated, five were regarded as high- or moderate-quality studies. Studies were deducted points due to low sample size and short-term follow-up although all RCTs showed statistically significant improvement of scars with treatment. Efficacious treatment modalities were CO~2~ ablative therapy and non-ablative laser therapy. Of the 21 observational studies, identified scores ranged from moderate- to very-low-quality studies. Again score variances identify issues of interstudy heterogeneity with regard to sample sizes, methodology, treatment outcome measures used, and methods of evaluating scar improvement. Lastly, most of the retrospective analysis and case report studies scored as low or very low quality due to the limitations of sample size and generalisability of results.

Discussion {#sec4-2054270414540139}
==========

Several key papers that discuss atrophic scarring focus on acne. Community-based studies report acne is prevalent in 90% of adolescent patients and can occur in any regions where there is an abundance of pilosebaceous glands such as the face, shoulders, back and chest. The process of acne is caused by various factors which increase sebum production of pilosebaceous glands such as increased systemic production of androgens and concomitant *Propionibacterium acnes* proliferation within follicles. The resultant infrainfundibular inflammatory process which ensues can cause follicular rupture or abscess formation. The wound healing process which then occurs can cause atrophic scars. In the adult population, 1% of patients are reported to have persistent acne scarring from adolescence.^[@bibr43-2054270414540139]^ The risk factors for developing scarring are multifactorial including a genetic predisposition to scarring, and a delay in acne treatment. The extent of scarring in acne can be reduced by early treatment during the inflammatory phase.

An observational study of normal scarring shows that histologically the scar maturation process occurs over a year with fibroblastic changes in dermal layers of skin; however, clinically the appearance remains unchanged except from diminishing erythema as angiogenesis ceases.^[@bibr44-2054270414540139]^ In addition, atrophic scarring is reported to worsen with age due to the natural lipoatrophy which further accentuates the scars.^[@bibr45-2054270414540139]^

Atrophic scars are defined histologically as scars showing a loss of collagen. They have been subclassified into the icepick scars which are the most prevalent subcategory at 60--70%, boxcar scars at 20--30% and rolling scars at 15--25%.^[@bibr46-2054270414540139]^ Icepick scars are described as a 'V shaped' extension scar into dermis whereas boxcar and rolling scars are more superficial with a wider base ([Figure 1](#fig1-2054270414540139){ref-type="fig"}). Figure 1.Subcategories of atrophic scars (adapted from Jacob et al.^[@bibr46-2054270414540139]^).

However, boxcar and rolling scars can be deep and all three subcategories can co-exist making clinical identification of type difficult. Histologically, atrophic scars exhibit thinning of the skin with a loss of collagen, elastin and deep dermal fat which cause a downward traction pull of the epidermis ([Figure 2](#fig2-2054270414540139){ref-type="fig"}). Atrophic scar formation over time can be demonstrated in [Figure 3](#fig3-2054270414540139){ref-type="fig"}. Figure 2.Immunostaining of anti-β-catenin in (a) atrophic scar and (b) keloid. Sparse staining in (a) correlates with reduced growth factor activity compared to (b). Haemotoxylin and eosin staining.^[@bibr47-2054270414540139]^ Histopathology of atrophic scar (a) and keloid (b). Scale bar: 100 μm Figure 3.Acne inflammatory lesions progressing to scars over time; (a) 0 weeks, (b) numbers of weeks from zero.^[@bibr48-2054270414540139]^ Figure 4.Bar chart showing percentages of various atrophic scar study types. Figure 5.Bar chart showing number of studies in each GRADE category.

The histological changes noted and described arise due to the inflammatory and reparative process of wound healing. The reparative phase is subdivided into (a) inflammation, (b) granulation and (c) matrix remodelling phases.

The main causes for patient distress from acne are facial disfigurement from inflammation, pigmentation and scarring. The psychosocial consequences resulting from acne were first recognised by Sulzberger and Zaidens.^[@bibr49-2054270414540139]^ A study examining the quality of life acne patients reported showed they experienced psychological and emotional morbidity comparable to chronic, disabling conditions such as epilepsy, diabetes and arthritic pain.^[@bibr50-2054270414540139]^ In addition, severe acne has been correlated with depression and suicidal ideation.^[@bibr51-2054270414540139]^ Patients can experience body dysmorphia due to the visible acne; however, the degree of psychological distress may not always correlate with the severity of acne and can be present in clinically mild acne causing low self-esteem and a reduced confidence to socialise.^[@bibr52-2054270414540139]^ Due to these recognised psychological comorbidities acne patients may have, it is important to offer holistic management and recognise psychological symptoms early.

Given the significant patient morbidity, our study highlights a lack of robust, good-quality evidence evaluating treatments. Overall, there is a lack of evidence evaluating treatment of this particular scar subcategory in comparison to keloid or hypertrophic scarring. In addition, there appears to be a lack of concrete pathophysiological knowledge of how atrophic scars occur and develop which could explain the paucity of treatment evidence as further biomolecular and pathological research examining the nature of atrophic scars needs to be conducted to further identify targets for treatment.

We chose the Clinical Evidence GRADE Score system to evaluate the quality of studies in our review over other scoring systems as we aimed to focus on outcome evidence of scar severity improvement, which clinicians could use to make judgements about efficacy of treatment for individual patients. Hence, the end scores assigned to each study do not take into account detailed analysis of methodology such as single or double blinding as well as wider practical issues such as treatment cost effectiveness. Two independent clinicians assigned each final score and crosschecked for congruence and in cases of discrepancy the paper was re-examined and the end score was achieved together. Despite this, the main disadvantage of the GRADE scoring system is that it is prone to being more subjective than other scores as it relies on the assessor's own judgement about certain criteria and where studies have very different methodologies comparison for scoring purposes can be difficult.

As is evident, there is a scarcity of RCTs and all are single blinded due to the nature of treatments subjected to trial; however, they provide a basis for further large-scale studies particularly with regard to the injectable therapies and the CROSS method of trichloroacetic acid (TCA) chemical peel therapy. Clearly, further RCTs with standardised methodology would need to be conducted before a meta-analysis of results can be compiled.

[Table 4](#table4-2054270414540139){ref-type="table"} is a visual summation of the results identified. In practice, it is very difficult to give clear guidelines of which treatment modality is best, as the choice of treatment will depend on individual patient characteristics such as skin tone, original scar location, previous treatment modalities experienced, overall treatment therapy duration, treatment downtime, side effects and their visibility, patient expectations of treatment and willingness to trial combination therapy. However, the evidence examined for this review does suggest a hierarchy of treatment in terms of efficacy. Table 4.Hierarchy of therapy for atrophic scars based on GRADE scores.TreatmentType of study and highest scoreCommentCO~2~ ablative therapyRCT (+5)Significantly effective (*p* \< 0.0001)Laser 1450 nm diode laser/Nd YAG laserRCTs (+5)Both treatments significantly effective (*p* = 0.008) but nil difference between two.Long-pulse/combined 585/1064 nmRCT (+4)Both treatments significantly effective (*p* \< 0.001) but nil difference between two.Glycolic acid/biweekly peelsRCT (+3)Both treatments significantly effective (*p* \< 0.001) but nil difference between two.Percutaneous collagen induction/trichloroacetic acidRCT (+3)Both treatments significantly effective (*p* \< 0.01) but nil difference between two.SubcisionObservational (+2)Significantly effective (*p* \< 0.041)[^4][^5] Table 5.Pros and cons of each treatment modality.TreatmentProsConsCO~2~ ablative therapy• Quick therapy• Multiple therapies less well tolerated• Side effects and longer downtimeNon-ablative laser• Quick therapy• May require increased treatment frequencies for end result• Minimal side effects• Can also improve skin wrinklingAutologous fat transfer• Use of patient's own fat• Dubious long-term maintenance of results• Good for forehead scarsDermabrasion• Quick therapy• Dubious long-term maintenance of results• Minimal side effects• Multiple therapies requiredChemical peels• Quick• Multiple therapies• Easy to administer• Increase in acid concentration less well tolerated• Side effects and longer downtimeInjectables• Quick• Nil significant research into efficacy, new treatment modality• Easy to administer• Initial results in literature are goodSubcision• Well known technique• Significant side effects and downtime• Easy to utilise• Delay in seeing end results• Discomfort during treatment• Multiple therapiesTretinoin iontophoresis• Good initial results• Technical procedure requiring specialist equipment and facilities• Dubious long-term treatment maintenance• Side effects

The main limitation of our study is the lack of total number of articles retrieved from which to draw a sound conclusion. However, we did not search for articles in other languages or non-published data rendering the results subject to publication bias. In addition, the scoring system used evaluates efficacy of treatment but not patient tolerance of treatment, which may affect options offered. For example, most patients did not tolerate CO~2~ ablative therapy well due to pain during and immediately after therapy as well as multiple side effects.

Conclusion {#sec5-2054270414540139}
==========

In summary, our review identifies an overall lack of published data regarding treatment of atrophic scarring and poor study methodology. Further research at a molecular level may be able to better define atrophic scarring and allow targeting of therapy. Our review allows the possible identification of areas where further RCTs may be conducted. Whilst our review reveals various treatment options which may be utilised to treat atrophic scarring, the ultimate choice of a particular treatment modality will depend on an individual patient's circumstances, preference and aims of treatment outcome.
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[^1]: Final score (quality of evidence) High = 4 points overall, Moderate = 3 points, Low = 2 points, Very low = 1 point or less.

[^2]: RCT: randomised controlled trial.

[^3]: RCT: randomised controlled trial; TCA: trichloroacetic acid.

[^4]: Other treatments (scores less than +2): autologous fat transfer, dermabrasion, injectables, tretinoin iontophoresis, subcision and artefiller and triple therapy.

[^5]: RCT: randomised controlled trial.
